{"id":"W4281263083","doi":"10.1016/j.jtct.2022.05.026","title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Legend Biotech; Pharmacyclics; Kite Pharma; MorphoSys; Daiichi-Sankyo; Miltenyi Biotec; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; TG Therapeutics; bluebird bio; Tessa Therapeutics; BeiGene; Atara Biotherapeutics; Kyowa Kirin Pharmaceutical Development; Janssen Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; National Cancer Institute; Servier; Gilead Sciences; Celgene; Novartis; AbbVie; Merck; Bristol-Myers Squibb; Cidara Therapeutics; AstraZeneca; Amgen; Seagen; Sierra Oncology; Astellas Pharma US","keywords":"Medicine; Internal medicine; Cohort; Odds ratio; Confidence interval; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01536202,0.0002302576,0.0004809159,0.0004984646,0.0002874224,0.001800628,0.0005972813,0.0007996811,0.003440204],"category_scores_gemma":[0.03246662,0.0001851703,0.001067933,0.0006639488,0.0009626504,0.0008341244,0.0007637038,0.00120237,0.0003170877],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001037162,"about_ca_system_score_gemma":0.001555131,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002069038,"about_ca_topic_score_gemma":0.005396742,"domain_scores_codex":[0.9895867,0.007954013,0.0008718212,0.0003958739,0.0009388774,0.0002526299],"domain_scores_gemma":[0.9528688,0.02743142,0.01387697,0.001530346,0.002499829,0.001792692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.09459931,0.003094844,0.407245,0.009751281,0.01115114,0.00050447,0.0006389868,0.003126381,0.001845469,0.004822045,0.02695215,0.4362691],"study_design_scores_gemma":[0.0265393,0.04527974,0.7493771,0.01202577,0.01435345,0.001735247,0.001959604,0.005482653,0.002410617,0.004332064,0.1363227,0.0001816798],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7258314,0.2204648,0.001213455,0.02785589,0.0008691571,0.0003056485,0.00470937,0.00006558033,0.01868469],"genre_scores_gemma":[0.9737176,0.01835483,0.0005653368,0.005139529,0.0003911042,0.00006121955,0.001405832,0.00001136446,0.0003532486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01536202,"threshold_uncertainty_score":0.0812431,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05882848758754067,"score_gpt":0.3396543056612309,"score_spread":0.2808258180736902,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}